Revolutionary medical innovations being unleashed in Canada MaRS discovery district
Health investors are paying attention to Canada, particularly to Toronto’s hot market.
This week, leading Canadian health startups will be the ones to watch during J.P. Morgan’s healthcare conference in San Francisco. More than two dozen health firms in MaRS’ network, from fields including artificial intelligence (AI), digital health and robotics, will be in Silicon Valley for the week of conferences and events.
Health investors are paying attention to Canada, particularly to Toronto’s hot market. According to Thomson Reuters, venture capitalists (VCs) invested over $1.1 billion in Canadian life-science companies in 2016, the most on record in a single year and double the amount of VC funding in 2015. There were also a record number of deals in 2017, particularly in AI and healthcare.
“Investors are beginning to take note of Toronto as an under-tapped market for health startups,” says Salim Teja, president of MaRS Ventures Services. “VCs and large health corporates globally are drawn to our capacities in science and healthcare delivery. We have a strong network of hospitals and research institutes in a highly concentrated area. Toronto is on par with leading health clusters and innovation hubs globally.”
MaRS is the world’s largest urban innovation hub, with 1.5 million sq ft dedicated to supporting multidisciplinary discoveries in the heart of Canada’s biggest city, next to the University of Toronto and dozens of research hospitals.
“VCs look to invest in transformative innovations that can significantly improve the diagnosis, treatment and prevention of disease,” says Brad Bolzon, managing director and chairman of the investment team at Versant Ventures. “In Canada, we’ve seen world-class science translated into startups that hold the promise of developing truly differentiated products for patients.”
Each year, hundreds of investors from around the world are drawn to Toronto for MaRS’ annual health startup showcase. This year’s Toronto Health Innovation Week, running 9-13 April, is expected to be the largest health investor gathering in Canada.
Here are some of the Canadian health companies descending on San Francisco during J.P. Morgan’s annual health conference.
Artificial intelligence in healthcareToronto-based health ventures are leveraging big data to transform medicine with new tools for doctors, patients and consumers. Diverse talent, leading research hospitals and innovation platforms like MaRS and the Vector Institute for Artificial Intelligence, along with vast troves of health data, are supporting Toronto’s emergence as a world-leading market for AI and health innovation. The following companies are combining machine learning and life science to develop new therapies, diagnostics and preventative treatments.
“2017 was a breakout year for Toronto, cementing its reputation as a global epicenter for AI innovation, particularly in life sciences,” says Naheed Kurji, president and CEO of Cyclica. “The field of artificial intelligence was pioneered by Toronto-based researchers, and their efforts have spurred much of the remarkable innovation we are seeing in the city today. The international venture capital ecosystem is taking note—2018 will be an exciting year.”
Therapeutics, devices and roboticsFrom the foundations of artificial intelligence and machine learning to the discovery of insulin and stemcells, Toronto has a history of medical and scientific breakthroughs. Today, sixteen of the world’s top 25 medical device makers call Toronto home. This includes Johnson & Johnson, Medtronic and GE Healthcare , as well as more than half of Canada’s estimated 1,100 medical device companies. The following innovators are developing products and therapies that will make a difference around the world.
Toronto is also a leading hub for digital health with innovators using technologies such as digital sensors and mobile medicine to empower patients and healthcare professionals. Here are a few of the companies with digital solutions that connect medical professionals, patients, records and research.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance